Navigation Links
Scarred for Life? Synedgen Hopes Not
Date:6/4/2013

Claremont, CA (PRWEB) June 04, 2013

Because burns tend to heal slowly, become infected and remain inflamed, they can produce scars that are excessive, physically debilitating and functionally damaging. Each year in the US, more than 1 million burn injuries require medical attention. While over the last several decades advances in life saving technology have improved outcomes for burn patients, methods to prevent scar formation have not kept pace.

With support from the US Army Medical Research and Materiel Command, Synedgen is working to accelerate the burn healing process. This contract will expand Synedgen’s pipeline wound care portfolio and facilitate studies to further demonstrate the extent of Synedgen’s novel polysaccharide derivative to reduce inflammation and provide enhanced healing with the reduction of scarring. Funding will also support analysis of cellular mechanisms of scar formation and how the product mitigates this process.

“There is an urgent need to address wound healing and scar reduction in burn patients, and we are eager to continue our product development to improve outcomes for these patients,” stated Synedgen president Shenda Baker. “Synedgen’s product has been demonstrated in vivo and in vitro to reduce inflammation and infection in dermal wounds and to increase healing with significant reduction of scar tissue. The product is designed to control the inflammation, both due to tissue damage and to bacteria, and accelerate the regenerative environment to prevent the emergence of excessive scar formation.”

This work is supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-13-C-0053. The views, opinions and/or findings contained in this release are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

About Synedgen

Synedgen Inc. is an innovative pharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10796834.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
2. Synedgen Announces Issuance of Patent to Optimize Animal Health
3. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... spanning the full spectrum of drug and device development, and Prism Clinical ... companies and clinicians, today announced Verified Clinical Trials (VCT) has been ...
(Date:1/18/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface and ... suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers real-world ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016 /PRNewswire/ ... que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que ... de tumor en 2017, con múltiples sitios previstos a lo largo ... ... en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que ...
Breaking Biology News(10 mins):